Navigation Links
The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
Date:9/3/2009

LAUSANNE, Switzerland, September 3 /PRNewswire/ -- Debiopharm Group, SA (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today presented the 'Debiopharm Life Sciences Award' to Dr Lluis Quintana-Murci from the Institut Pasteur in France, for his outstanding innovative research in the emerging field of evolutionary genetics of infection. Funded by Debiopharm, the ceremony took place at the EPFL (Ecole Polytechnique Federale de Lausanne) during the EPFL School of Life Sciences Inaugural Symposium. Dr Quintana-Murci and his institute received a total of CHF 100'000.

Dr Quintana-Murci leads the research unit of "Human Evolutionary Genetics" within the Department of Genomes and Genetics at the Pasteur Institute in Paris. His work focuses on understanding the mechanisms of host defence and infection in the natural setting, namely how pathogens have exerted selective pressures on human genes involved in immunity or host-pathogen interactions. In the past, scientists have used cellular and molecular biology, immunology or classical genetics to study the biology and immunology of infection. Dr Quintana-Murci has used a novel approach called "evolutionary genetics of infection" that has helped in the understanding of how pathogens have contributed to shape the human genome. A direct consequence of his work is the identification of a number of genes that are the key players of host defence against infection.

"We were impressed by the work of Dr Quintana-Murci and his colleagues," said Dr Rolland-Yves Mauvernay, President and Founder of Debiopharm Group. "He has taken the study of host-pathogen interactions to a higher level, where the pathogen is now recognised as a key driver of genetic selection. His novel and original approach of studying infection biology may have direct implications in the development of future treatments against infectious diseases."

According to Professor Didier Trono, Dean of the Life Sciences Faculty at the EPFL, "Following the momentum created by the sequencing of the human genome and capitalising on new technologies of high throughput DNA analysis, the studies conducted by Dr Lluis Quintana-Murci teach us about the history of humanity and its struggles against pathogens. They suggest new therapeutic avenues for the control of infectious diseases."

"Receiving the Debiopharm Life Sciences Award encourages us to go further in our research on the correlation between genetic variation in human genes and our chances to develop an infectious disease. This information is critical to a more precise development of vaccines and therapeutics concerning these microbial sensors. Most importantly, this prize honours the field of human evolutionary genetics by recognising it as an indispensable complement to the clinical and epidemiological genetics of infection," added Dr Quintana-Murci.

About the Debiopharm Life Sciences Award

The Award was set up in 2006 to mentor and motivate young innovative European researchers in the field of life sciences. Criteria for applications include novelty and originality of the work, as well as its importance and significance in connection with targeted therapeutic fields.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

    Debiopharm S.A. Contact
    Maurice Wagner
    Director Corporate Affairs & communication
    Tel.: +41(0)21-321-01-11
    Fax: +41(0)21-321-01-69
    mwagner@debiopharm.com

    Additional Media Contacts
    In London
    Maitland
    Brian Hudspith
    Tel: +44(0)20-7379-5151
    bhudspith@maitland.co.uk

    In New York
    Russo Partners, LLC
    Martina Schwarzkopf, Ph.D.
    Account Executive
    Tel: +1-212-845-4292
    Fax: +1-212-845-4260
    martina.schwarzkopf@russopartnersllc.com



'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
2. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
3. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
4. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
5. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
6. Japanese Cancer Association and Debiopharm Honour Japanese Research
7. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
8. Debiopharm and EPFL Establish an Oncology Chair
9. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
10. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
11. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® test, ... clinically significant acute bacterial and viral respiratory tract infections by testing the ...
(Date:10/11/2017)... ... 2017 , ... At its national board meeting in North ... the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology and ... ARCS Alumni Hall of Fame . ASTER Labs is a technology development ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... TX (PRWEB) , ... October 11, 2017 , ... ... August compared the implantation and pregnancy rates in frozen and fresh in ... contribution of progesterone and maternal age to IVF success. , After comparing the ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):